J Korean Pediatr Soc.  1982 May;25(5):467-476.

Bronchial asthma, Atopic dermatitis, HLA type

Affiliations
  • 1Department of Pediatrics, Wallace Memorial Baptist Hospital, Busan, Korea.

Abstract

We observed 285 cases of culture proved shigellosis from Jan. 1978 to July 1981 at W.M.B.H. in Busan. We specially observed the clinical and bacteriological response to Oxolinic acid in 59 cases from Jan. to July 1981. The following results were obtained. 1. The most commonly isolated shigella strains was Sh. flexneri (85.3%) followed by Sh. sonnei (7.4%), Sh. boydii (4.2%) and Sh. dysenteriae(3.2%). 2. Antibiotic sensitivity test revealed that more than 90% of strains were resistant to Tetracycline, Chloramphenicol and Ampicillin. Resistance strains to Gentamycin and Oxocid were found in less than 12.2% and 14.3% respectively. 3. The multiple antibiotic resistant strains were observed in about 80% of 59 strains, which were resistant to 3~5 antibiotics. The most of these strains were resistant to Ampicillin, Chloramphenicol and Tetracycline. In 3 cases it was resistant to all kinds of antibiotics but oxolinic acid. 4. Oxolinic acid showed growth-inhibitory zone of more than 11 mm with the concentration of 2mcg/ml in 95% and M.I.C. value of less than 0.76mcg/ml in 90%. 5. After administration of Oxolinic acid, there was clinical response within 2 days in 76.5% and conversion to negative stool culture within 2days in 68.8%. 6. Compared with placebo group, there was parallel clinical and bacteriologic effectiveness between Oxolinic acid and Rifampin.

Keyword

Shigellosis; Oxolinic acid

MeSH Terms

Ampicillin
Anti-Bacterial Agents
Asthma*
Busan
Chloramphenicol
Dermatitis, Atopic*
Dysentery, Bacillary
Gentamicins
Oxolinic Acid
Rifampin
Shigella
Tetracycline
Ampicillin
Anti-Bacterial Agents
Chloramphenicol
Gentamicins
Oxolinic Acid
Rifampin
Tetracycline
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr